Trillium Therapeutics Reports Third Quarter 2017 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
373
Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results

TORONTO, ONTARIO--(Marketwired - Nov. 10, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September 30, 2017.

"Our strategy of running intravenous and intratumoral signal-seeking Phase 1 trials of TTI- 621 in multiple indications gives us the best opportunity to identify malignancies where we can further focus our clinical efforts," said Dr. Niclas Stiernholm, Trillium's Chief Executive Officer. "We are on track to provide additional clinical updates by year end."

Upcoming Clinical Events in the Fourth Quarter of 2017:

  • Preliminary data from the TTI-621 Phase 1a intratumoral dose escalation trial in solid tumors to be presented at the American Society of Hematology 59th Annual Meeting
  • Additional clinical data from the TTI-621 Phase 1b intravenous trial to be presented at the American Society of Hematology 59th Annual Meeting
  • IND submission for TTI-622

Third Quarter 2017 Financial Results

As of September 30, 2017, Trillium had cash and marketable securities of $64.3 million compared to $50.5 million at December 31, 2016. The increase in cash and marketable securities was due mainly to receiving net proceeds of $39.0 million from the June 2017 financing, partially offset by cash used in operations of $20.4 million and an unrealized foreign exchange loss of $4.5 million.

Net loss for the nine months ended September 30, 2017 of $34.4 million was higher than the loss of $22.7 million for the nine months ended September 30, 2016. The net loss was higher due mainly to higher research and development expenses of $6.8 million with two active Phase 1 trials for TTI-621 and manufacturing expenses for TTI-622 in 2017, the recognition of a deferred tax recovery in the nine months ended September 30, 2016 related to the acquisition of Fluorinov of $3.7 million, and a higher net foreign currency loss of $1.8 million.

Selected Consolidated Financial Information:
Consolidated statements of loss and comprehensive loss
Amounts in thousands of Canadian dollars Nine months ended September 30, 2017 Nine months ended September 30, 2016
Research and development expenses $27,324 $20,527
General and administrative expenses 2,607 3,016
Net finance costs 4,499 2,847
Income tax expense (recovery) - (3,681 )
Net loss and comprehensive loss for the period 34,430 22,709
Basic and diluted loss per common share 3.77 2.91
Consolidated statements of financial position
As at As at
Amounts in thousands of Canadian dollars September 30, 2017 December 31, 2016
Cash and marketable securities $64,297 $50,473
Total assets 77,433 66,623
Total equity 64,718 58,119

About Trillium Therapeutics

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti- tumor effects by pro-phagocytic ("eat") signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company's most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

For more information visit: www.trilliumtherapeutics.com

Caution Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of applicable United States securities laws and forward-looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements in this press release include statements about, without limitation, Trillium's expected timing of upcoming clinical events. With respect to the forward-looking statements contained in this press release, Trillium has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical and clinical trials; and the completeness, accuracy and usefulness of the data. While Trillium considers these assumptions to be reasonable, these assumptions are inherently subject to significant scientific, business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors that could cause Trillium's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained in this press release. Known risk factors include, among others: positive preliminary results from early-stage clinical trials may not be indicative of the final results from the trial or be indicative of favorable outcomes in later-stage clinical trials and data are subject to audit for inclusion in the final clinical trial database; clinical data may not demonstrate adequate efficacy and safety to result in regulatory approval to market any of our product candidates in any jurisdiction; given the early stage of Trillium's product development, there can be no assurance that its research and development programs will result in regulatory approval or commercially viable products and that Trillium can adequately demonstrate TTI-621's individual contribution in a combination therapy; clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested drug candidate; Trillium may not receive the necessary regulatory approvals for the clinical development of Trillium's products; economic and market conditions may worsen; and market shifts may require a change in strategic focus.

A more complete discussion of the risks and uncertainties facing Trillium appears in Trillium's Annual Report on Form 20-F and Trillium's continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov . All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Trillium disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Trillium Therapeutics Inc. James Parsons Chief Financial Officer 416-595-0627 x232 james@trilliumtherapeutics.com www.trilliumtherapeutics.com Mark Corbae Canale Communications for Trillium Therapeutics 619-849-5375 mark@canalecomm.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 158

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 91

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 128

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 202

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
BET's HBCU Basketball Bet Is Bigger Than Six Games

Updated Category News Views 46

December television usually hands the microphone to the same old basketball machinery, which makes BET putting HBCU hoops in primetime feel overdue rather than merely promotional. Beginning December 3 at 8:00 p.m. ET, BET and Straight Shooter Media will air a six-game series built around Howard University and a rotating slate of opponents. The opener is Grambling State...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 0

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 39

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 77

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading

Top 5 Most Recently Viewed Articles

BD Settles SEC Investigation While Strengthening Operations

Updated Category News Views 215

BD Reaches Settlement with the SEC BD (Becton, Dickinson and Company) (NYSE: BDX), a renowned leader in medical technology, has announced a significant agreement to resolve an investigation by the U.S. Securities and Exchange Commission (SEC). This follows concerns regarding prior public disclosures related to the BD Alaris™ System. Key Details of the Resolution The...

Continue Reading
Seizing the Managed Detection and Response Market Opportunity

Updated Category News Views 232

Unlocking the Managed Detection and Response Market Potential Middleton, Massachusetts – QKS Group, a leading market intelligence and advisory firm, recently released an insightful report on the global Managed Detection and Response (MDR) Market. This comprehensive analysis targets industry leaders eager to tap into a rapidly growing sector. According to their findings,...

Continue Reading
Expanding Horizons: Coldwell Banker's Venture into Africa

Updated Category News Views 94

Coldwell Banker Real Estate's New Milestone Coldwell Banker Tanzania and Zanzibar have officially joined the growing network of Coldwell Banker Real Estate LLC, marking an exciting expansion into Africa. This new master franchise embodies the brand’s ongoing commitment to deliver top-tier real estate services on an international scale. Seizing Growing Markets The real...

Continue Reading
Automotive Grade Linux Unveils SoDeV Platform for Advancements

Updated Category News Views 289

Automotive Grade Linux Introduces SoDeV for Software Defined Vehicles In an exciting development for the automotive industry, Automotive Grade Linux (AGL) has launched SoDeV, an open-source reference platform aimed at significantly enhancing the development of Software Defined Vehicles (SDVs). This innovative platform allows developers to focus on software-first...

Continue Reading
Exploring Promising Tech Stocks Ahead of Future Opportunities

Updated Category News Views 257

Opportunity in Oversold Tech Stocks The information technology sector is witnessing a notable shift, with several stocks currently considered undervalued. These oversold stocks represent potential opportunities for savvy investors looking to capitalize on future growth. By focusing on these stocks, investors can identify undervalued companies that have the potential for...

Continue Reading